Navigation Links
XYOTAX in Medical News

Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results

...operating expenses in 2008, by focusing resources on reaching $15 million in net Zevalin revenues, pursuing European marketing authorization (MAA) for xyotax (paclitaxel poliglumex, CT-2103), preparing for a potential U.S. marketing application (NDA) for pixantrone (BBR 2778) in 2009, and supporting the adv...

Cell Therapeutics, Inc. (CTI) Cuts Net Operating Expenses 35% and Expands Commercial Team to Support Zevalin(R) Sales and Applications Seeking Two Product Approvals in 2009

...tates and preparing the marketing applications for xyotax (paclitaxel poliglumex, CT-2103) and pixantrone (B... some phase III clinical trials for pixantrone and xyotax until planned regulatory filings and the completio...uct approvals. CTI expects to file for approval of xyotax in Europe in March. The Company will expand its co...

Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.'s Drug Pipeline

... O'Byrne, M.D., presented the phase III results of xyotax in first-line treatment of non-small cell lung can...." Dr. O'Byrne also presented data suggesting that xyotax may be particularly effective in women with pre-me...ate. Based on preclinical studies, it appears that xyotax is preferentially distributed to tumors due to the...

Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financial Results

...ion of ZEVALIN, coupled with progress on advancing xyotax toward a first half 2008 marketing application sub... phase III clinical trials, PGT307 and PIX303, for xyotax and pixantrone (BBR 2778), respectively. Including...pared to currently marketed anthracyclines. About xyotax XYOTAX(TM) (paclitaxel poliglumex) is a biologica...

Multiple deaths forces cancer trial to be called off

...d in a big way with enrollment made at 170 medical centers globally last April, and had planned to study about 600 patients to prove the efficacy of xyotax in increasing the life span of patients with lung cancer using a regularly used chemotherapy agent coupled with a polymer which is supposed to help in...

Experimental Drug Reduces Tumor Size When Given With Radiation

... An experimental drug xyotax was successful in shrinking stomach and esophagus tumors in four out of 12 cancer patients, according to its maker Cell Therapeutics.// The other pati...
XYOTAX in Medical Technology

European Regulatory Agency Accepts Cell Therapeutics, Inc.'s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review

... beginning of March. The validation of the MAA for xyotax initiates the marketing approval review process, w...of the MAA. In the STELLAR 4 trial, single-agent xyotax resulted in comparable survival to gemcitabine or ...tor support. In addition to improved tolerability, xyotax offered more convenient administration compared to...

Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)

... xyotax to be reviewed for PS2 first-line non-small cell l...LAR trials. In the STELLAR 4 trial, single-agent xyotax resulted in comparable survival to gemcitabine or ...tor support. In addition to improved tolerability, xyotax offered more convenient administration compared to...

Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill

...atment for lung cancer. Data collected from recent xyotax trials suggests that estrogen levels may alter the...they respond differently to treatment. Through our xyotax studies, we continue to explore ways to turn a neg...ate. Based on preclinical studies, it appears that xyotax is preferentially distributed to tumors due to the...

Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill

...atment for lung cancer. Data collected from recent xyotax trials suggests that estrogen levels may alter the...they respond differently to treatment. Through our xyotax studies, we continue to explore ways to turn a neg...ate. Based on preclinical studies, it appears that xyotax is preferentially distributed to tumors due to the...

XYOTAX More Cost Effective With Fewer Side Effects Than Gemcitabine or Vinorelbine in Treating Non-Small Cell Lung Cancer

...source utilization (MRU) and associated costs with xyotax (paclitaxel polyglumex) treatment compared to gemc... average treatment cost, excluding drug costs, for xyotax patients was nearly half the cost of treatment for...tional, randomized trial (STELLAR 4) that compared xyotax (n=191) to gemcitabine or vinorelbine (n=190) in p...
XYOTAX in Biological Technology

Veteran Drug Industry Executive to Become President of CTI

...ation for FDA approval in late 2008 or early 2009. xyotax is also being studied independently in a phase III... negotiate an exclusive license for pixantrone. If xyotax receives regulatory approval in the U.S. or Europe...ir intended uses, a determination by the EMEA that xyotax should not be approved for sale in Europe, other d...

Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008

...resources to the GOG212 trial, a clinical trial of xyotax in first-line maintenance ovarian cancer being per... in the second half of 2009. The clinical trial of xyotax in combination with carboplatin in women with pre-...for the Company is to focus resources on obtaining xyotax and pixantrone approval with existing or completin...

Cell Therapeutics, Inc. (CTI) to Submit Marketing Authorization Application for XYOTAX(TM) for First-line Non-small Cell Lung Cancer Ahead of Schedule

...he STELLAR 4 phase III clinical trial results, for xyotax as a single agent for first-line treatment of non-...al The STELLAR 4 phase III clinical trial tested xyotax versus either gemcitabine or vinorelbine for the p...ate. Based on preclinical studies, it appears that xyotax is preferentially distributed to tumors due to the...

Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer

... significantly shorter than post-menopausal women. xyotax (TM) (paclitaxel poliglumex) will be studied in co...tion (MAA) in Europe in the first half of 2008 for xyotax as a single agent for first-line treatment of NSCL... 225 patients will be randomized to receive either xyotax 175mg/m2 plus carboplatin (AUC6) or paclitaxel 225...
Other Tags
(Date:8/1/2014)... NY (PRWEB) August 01, 2014 Millions ... that affects the legs and in some cases the ... estimates state that about 17 million women in the ... of women dealing with the pain, embarrassment and discomfort ... and even some physicians are unaware that this is a ...
(Date:8/1/2014)... 01, 2014 Register to join the webinar ... most active years on record for life sciences investing. IPOs ... represented 22 percent of all venture dollars spent in 2013. ... high valuations. , However, 2014 is proving more of ... by Silicon Valley Bank, while life sciences IPOs are losing ...
(Date:7/31/2014)... 1, 2014) Women over the age of 65 ... for obesity, greater struggles against poverty and higher rates ... in the August issue of Annals of Allergy, ... American College of Allergy, Asthma and Immunology (ACAAI), outlines ... and offers practical solutions to improve their care. ...
(Date:7/31/2014)... The 2013 PolyU TSI hit ... from 75.07 in 2012. The index measures inbound ... integrates them into an overall index. The 2013 ... satisfied with Hong Kong over time. , The ... service performance in Hong Kong are attractions (79.27) ...
(Date:7/31/2014)... Ce-Classes.com has announced that they are now ... a Systematic Review of Sexual Satisfaction . ... International Journal of Clinical and Health Psychology. , This ... need to have accurate information about sexual satisfaction so ... The material provides a systematic review of 197 ...
Breaking Medicine News(10 mins):Health News:Lipedema Centers Works With Insurers To Gain Coverage For Lipedema Treatment 2Health News:Register to Join the Merrill DataSite's Webinar - Built to Sell: The Life Sciences Deal Climate 2Health News:Register to Join the Merrill DataSite's Webinar - Built to Sell: The Life Sciences Deal Climate 3Health News:Female baby boomers with asthma? You may need help 2Health News:Female baby boomers with asthma? You may need help 3Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 2Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 3Health News:Company Provides New Course on Sexual Satisfaction 2Health News:Company Provides New Course on Sexual Satisfaction 3
(Date:7/31/2014)... the United States, natural-gas production from shale rock ... 2007. Yet scientists still do not fully understand ... to a report in the journal Frontiers ... gas extraction continues to vastly outpace scientific examination, ... organizations and institutions, including Princeton University, concluded that ...
(Date:7/31/2014)... By tracing nearly 3,000 genes to the earliest ... Florida scientists have created an extensive "Tree of ... next-generation DNA sequencing. , Among the study,s ... to small moths than to large ones, which ... The study also found that some insects once ...
(Date:7/31/2014)... study (HPV-023; NCT00518336) shows the sustained efficacy, ... virus (HPV) vaccine Cervarix. Women vaccinated with ... more than nine years, and vaccine efficacy ... is the longest follow-up report for a ... for the full paper. , HPV ...
Breaking Biology News(10 mins):'Fracking' in the dark: Biological fallout of shale-gas production still largely unknown 2'Fracking' in the dark: Biological fallout of shale-gas production still largely unknown 3UF study advances 'DNA revolution,' tells butterflies' evolutionary history 2UF study advances 'DNA revolution,' tells butterflies' evolutionary history 3Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3
Other Contents